Capital Fund Management (CFM)’s Ligand Pharmaceuticals LGND Stock Holding History

Capital Fund Management (CFM)’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-5,931	Closed	-$368K	–	1933
2019 Q3	$368K	Sell	5,931 -1,443	-20%	-$90.6K	﹤0.01%	1351
2019 Q2	$525K	Sell	7,374 -962	-12%	-$70.9K	﹤0.01%	1204
2019 Q1	$654K	Buy	8,336 +5,611	+206%	+$425K	0.01%	1166
2018 Q4	$231K	Sell	2,725 -12,183	-82%	-$1.3M	﹤0.01%	1706
2018 Q3	$2.55M	Buy	14,908 +5,290	+55%	+$798K	0.01%	1015
2018 Q2	$1.24M	Buy	+9,618	New	+$1.07M	0.01%	1256
2017 Q1	–	Sell	-3,687	Closed	-$234K	–	1666
2016 Q4	$234K	Buy	+3,687	New	+$233K	﹤0.01%	1517

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Capital Fund Management (CFM)'s LGND Position: Q3 2019 in Review

Capital Fund Management (CFM) sold out of Ligand Pharmaceuticals (LGND) in Q3 2019, closing a stake of 3,334 shares — an estimated $209K sold.

Capital Fund Management (CFM) first reported a position in LGND in Q3 2014 and held it in 9 quarters. The position peaked at $1.66M in Q3 2016. 275 funds tracked by Wall St. Rank hold LGND as of Q3 2019.

Capital Fund Management (CFM) reported no remaining Ligand Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Capital Fund Management (CFM) sold 3,334 Ligand Pharmaceuticals shares in Q3 2019, an estimated $209K.
Capital Fund Management (CFM) first reported a position in Ligand Pharmaceuticals in Q3 2014 and held it in 9 quarters.
Capital Fund Management (CFM)'s Ligand Pharmaceuticals position peaked at $1.66M in Q3 2016.
275 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2019.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2019, filed 13 Nov 2019.